France fights to prevent approval of Orexigen's obesity drug
This article was originally published in Scrip
Executive Summary
France is pursuing its efforts to prevent the approval of Orexigen's weight loss combination product Mysimba (naltrexone/bupropion) on safety and efficacy grounds, and has taken the matter to the European Commission's Standing Committee on Medicinal Products for Human Use.